Nature Communications (Feb 2023)

Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

  • Juliann Chmielecki,
  • Tony Mok,
  • Yi-Long Wu,
  • Ji-Youn Han,
  • Myung-Ju Ahn,
  • Suresh S. Ramalingam,
  • Thomas John,
  • Isamu Okamoto,
  • James Chih-Hsin Yang,
  • Frances A. Shepherd,
  • Krishna C. Bulusu,
  • Gianluca Laus,
  • Barbara Collins,
  • J. Carl Barrett,
  • Ryan J. Hartmaier,
  • Vassiliki Papadimitrakopoulou

DOI
https://doi.org/10.1038/s41467-023-35962-x
Journal volume & issue
Vol. 14, no. 1
pp. 1 – 8

Abstract

Read online

In the phase III AURA3 study (NCT02151981), the third-generation epidermal growth factor receptor tyrosine kinase inhibitor osimertinib prolonged progression-free survival versus platinum-doublet chemotherapy in patients with EGFR T790M advanced NSCLC. Here, by next-generation sequencing of circulating tumor DNA, the authors assess candidate mechanisms of acquired resistance to osimertinib in patients from the AURA3 trial.